The iROCK Registry
Research type
Research Study
Full title
Stereotactic Ablative Radiotherapy (SABR) in Renal Cell Carcinoma (RCC): International Radiosurgery Oncology Consortium for Kidney (iROCK) Prospective Registry
IRAS ID
361744
Contact name
Shankar Siva
Contact email
Sponsor organisation
Peter MacCallum Cancer Institute
Clinicaltrials.gov Identifier
HREC Reference: HREC/80137/PMCC-2021, Peter MacCallum Cancer Centre Human Research Ethics Committee
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
The IROCK Registry is an international research database, that will collect clinical data from the medical records of patients treated with stereotactic ablative radiotherapy (SABR) for Renal Cell Carcinoma (RCC) or kidney cancer. The aim is to address continuous improvements in this treatment to improve patient information and outcomes.
This is an international academic real-world data initiative led by Peter MacCallum Cancer Centre, Victoria, Australia. The Royal Marsden Hospital, London are the UK leading site, but patients can be included from across any registered treating centre in the UK. Renal SABR has now gained international recognition as a non-invasive option for the curative-intent treatment of primary RCC. Standard of care curative-intent treatment for kidney cancer is invasive surgery, however many patients are older, more frail and or/have multiple comorbidities which preclude them for surgery.
The iROCK registry primarily aims to evaluate long-term cancer control and harms of treatment in a real world setting. Patients, at participating institutions, who have undergone SABR for RCC and fulfil the inclusion criteria as per the protocol will be enrolled by their treating institution. Individual participants will not be approached for inclusion. De-identified data will be extracted from patient’s medical records and entered into a purpose built, secure, web-based database i.e. no identifiable personal details will be shared. There are no interventional aspects outside of standard of care; there are no additional visits or research scans. Participants are only included if they have not opted out for use of their data through NHS National Data Opt Out.
IROCK registry data will provide a better understanding of the biology underlying SABR. We will also collect critical data to inform on renal function outcomes, and document novel combinations of systemic targeted agents and/or immunotherapies to establish their ability to enhance the effectiveness of the SABR technique.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
25/EE/0248
Date of REC Opinion
23 Dec 2025
REC opinion
Further Information Favourable Opinion